Phlow Corp., a pharmaceutical CDMO, has expanded its labs in the Virginia Biotechnology Research Park in Richmond, VA, by acquiring additional analytical capabilities, including advanced spectroscopy tools and high-resolution, high-mass accuracy mass spectrometry. This enhancement allows Phlow to streamline processes and foster greater collaboration.
This expansion more than doubles the size of the company and now employs over 90+ highly skilled scientists and professionals.
Additionally, the company continues to invest in its cGMP kilo-scale and metric-ton scale manufacturing infrastructure in Petersburg, VA, and has selected the technology solutions provider Apprentice to provide its AI-driven Manufacturing Execution System (MES). Integrating AI with next-gen MES capabilities and seamless connectivity to other Industry 4.0 tools aligns with Phlow’s digital transformation goals and enables end-to-end manufacturing innovation. The next-gen MES platform aims to allow Phlow to accelerate production timelines, improve quality, and scale new products faster than before.
“The integration of AI-driven MES technology will further enhance Phlow’s ability to streamline operations, reduce costs, and improve product quality,” said Juan Piacquadio, Vice President and Chief Information Officer of Phlow. “With our technology partner, we’re helping to fortify the U.S. pharmaceutical supply chain with thoughtfully applied artificial intelligence and advanced manufacturing technologies.”
